Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

Market Cap	13.05B
Revenue (ttm)	1.84B
Net Income (ttm)	487.28M
Shares Out	316.05M
EPS (ttm)	1.58
PE Ratio	26.16
Forward PE	19.04
Dividend	0.64 (1.56%)
Ex-Dividend Date	Jun 12, 2025

Volume	3,340,481
Average Volume	6,145,962
Open	41.19
Previous Close	41.19
Day's Range	41.01 - 41.90
52-Week Range	29.86 - 58.21
Beta	0.52
RSI	41.96
Earnings Date	Oct 22, 2025

About SHA:688076

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers APIs, including peptides, small molecules, and oligonucleotides; and intermediate products, such as fulvestrant, oseltamivir, and other intermediates. It also provides CRDMO/CMO services. The company was founded in 2009 and is headquartered in Hangzhou City, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 2,028
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688076

Financial Performance

In 2024, SHA:688076's revenue was 1.62 billion, an increase of 57.21% compared to the previous year's 1.03 billion. Earnings were 404.39 million, an increase of 148.19%.